Short answer
Day One Biopharmaceuticals, Inc. (DAWN) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $40M (down 61.0% year over year) with net income of −$20M.
Q3 2025 key financials · XBRL
- Revenue
- $40M
- −61.0% YoY · +17.4% QoQ
- Net income
- −$20M
- −153.3% YoY · +34.9% QoQ
- Operating margin
- -60.9%
- EPS (diluted)
- −$0.19
- −143.2% YoY · +34.5% QoQ
Source: XBRL data from the Day One Biopharmaceuticals, Inc. (DAWN) Q3 2025 10-Q on SEC EDGAR. USD.
Day One Biopharmaceuticals, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New licensing risk: Acquisition of DAY301 license from MabCare Therapeutics in June 2024 adds development and commercialization uncertainties
- Updated financial risk: Net loss increased to $86.0 million for nine months ended Sept 30, 2025 vs $29.8 million prior year, reflecting higher R&D and commercialization costs
- Regulatory risk: FDA approved OJEMDA in April 2024 for pLGG with BRAF mutations; post-marketing commitments and potential requirements pose ongoing compliance risks
- Operational risk: Early commercialization stage with challenges in manufacturing scale-up, sales, marketing, and supply chain for OJEMDA and DAY301
- Liquidity risk: $451.6 million cash and equivalents as of Sept 30, 2025, sufficient for at least 12 months; future capital needs depend on clinical progress and market conditions
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.